BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 31466073)

  • 1. Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer.
    Rosenhammer B; Niessen C; Rotzinger L; Reiss J; Schnabel MJ; Burger M; Bründl J
    Urol Int; 2019; 103(3):270-278. PubMed ID: 31466073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1.
    Apfelbeck M; Clevert DA; Ricke J; Stief C; Schlenker B
    Clin Hemorheol Microcirc; 2018; 69(1-2):93-100. PubMed ID: 29660918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS-fusion control biopsies: A prospective evaluation.
    von Hardenberg J; Westhoff N; Baumunk D; Hausmann D; Martini T; Marx A; Porubsky S; Schostak M; Michel MS; Ritter M
    Urol Oncol; 2018 Sep; 36(9):401.e1-401.e9. PubMed ID: 30093211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial.
    Westhoff N; Ernst R; Kowalewski KF; Derigs F; Neuberger M; Nörenberg D; Popovic ZV; Ritter M; Stephan Michel M; von Hardenberg J
    Eur Urol Focus; 2023 Mar; 9(2):283-290. PubMed ID: 36344395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation.
    Khandwala YS; Morisetty S; Ghanouni P; Fan RE; Soerensen SJC; Rusu M; Sonn GA
    Urol Oncol; 2022 Nov; 40(11):489.e9-489.e17. PubMed ID: 36058811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of intraoperative contrast-enhanced ultrasound in detecting residual disease after focal HIFU for localized prostate cancer.
    Bacchetta F; Martins M; Regusci S; Jichlinski P; Meuwly JY; Lucca I; Valerio M
    Urol Oncol; 2020 Nov; 38(11):846.e1-846.e7. PubMed ID: 32532530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up after focal therapy of the prostate with high intensity focused ultrasound (HIFU) using contrast enhanced ultrasound (CEUS) in combination with MRI image fusion.
    Apfelbeck M; Chaloupka M; Schlenker B; Stief CG; Clevert DA
    Clin Hemorheol Microcirc; 2019; 73(1):135-143. PubMed ID: 31561350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High intensity focused ultrasound with Focal-One
    Perez-Reggeti JI; Sanchez-Salas R; Sivaraman A; Linares Espinos E; de Gracia-Nieto AE; Barret E; Galiano M; Rozet F; Fregeville A; Renard-Penna R; Cathala N; Mombet A; Prapotnich D; Cathelineau X
    Actas Urol Esp; 2016 Dec; 40(10):608-614. PubMed ID: 27543259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy.
    Shah TT; Kanthabalan A; Otieno M; Pavlou M; Omar R; Adeleke S; Giganti F; Brew-Graves C; Williams NR; Grierson J; Miah H; Emara A; Haroon A; Latifoltojar A; Sidhu H; Clemente J; Freeman A; Orczyk C; Nikapota A; Dudderidge T; Hindley RG; Virdi J; Arya M; Payne H; Mitra A; Bomanji J; Winkler M; Horan G; Moore CM; Emberton M; Punwani S; Ahmed HU
    Eur Urol; 2022 Jun; 81(6):598-605. PubMed ID: 35370021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.
    Dickinson L; Ahmed HU; Hindley RG; McCartan N; Freeman A; Allen C; Emberton M; Kirkham AP
    Urol Oncol; 2017 Jan; 35(1):30.e9-30.e15. PubMed ID: 27663393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation.
    Scheltema MJ; Chang JI; van den Bos W; Böhm M; Delprado W; Gielchinsky I; de Reijke TM; de la Rosette JJ; Siriwardana AR; Shnier R; Stricker PD
    Eur Urol Focus; 2019 Jul; 5(4):585-591. PubMed ID: 29102671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does mpMRI guidance improve HIFU partial gland ablation compared to conventional ultrasound guidance? Early functional outcomes and complications from a single center.
    Sivaraman A; Marra G; Stabile A; Mombet A; Macek P; Lanz C; Cathala N; Moschini M; Carneiro A; Sanchez-Salas R; Cathelineau X
    Int Braz J Urol; 2020; 46(6):984-992. PubMed ID: 32822127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    Guillaumier S; Peters M; Arya M; Afzal N; Charman S; Dudderidge T; Hosking-Jervis F; Hindley RG; Lewi H; McCartan N; Moore CM; Nigam R; Ogden C; Persad R; Shah K; van der Meulen J; Virdi J; Winkler M; Emberton M; Ahmed HU
    Eur Urol; 2018 Oct; 74(4):422-429. PubMed ID: 29960750
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Burger IA; Müller J; Donati OF; Ferraro DA; Messerli M; Kranzbühler B; Ter Voert EEGW; Muehlematter UJ; Rupp NJ; Mortezavi A; Eberli D
    J Nucl Med; 2019 Aug; 60(8):1118-1123. PubMed ID: 30683764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Exploratory Study of Dose Escalation
    Huber PM; Afzal N; Arya M; Boxler S; Dudderidge T; Emberton M; Guillaumier S; Hindley RG; Hosking-Jervis F; Leemann L; Lewi H; McCartan N; Moore CM; Nigam R; Odgen C; Persad R; Thalmann GN; Virdi J; Winkler M; Ahmed HU
    J Endourol; 2020 Jun; 34(6):641-646. PubMed ID: 32253928
    [No Abstract]   [Full Text] [Related]  

  • 16. [HIFU therapy of localized prostate cancer using image-guided robotic HIFU Focal One].
    Govorov AV; Vasilyev AO; Alaverdyan AI; Kolontarev KB; Pushkar DY
    Urologiia; 2023 May; (2):83-89. PubMed ID: 37401710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Systematic Control Biopsies following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
    Rompré-Brodeur A; Marcq G; Tholomier C; Fugaru I; Loutochin O; Anidjar M; Bladou F
    J Urol; 2021 Nov; 206(5):1177-1183. PubMed ID: 34251879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Whole-Gland High-Intensity Focused Ultrasound vs Whole-Gland High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: 1-Year Oncological and Functional Outcomes.
    Lei Y; Zanker P; Yildiz S; Hancke K; Seidl D; Koch O; Schwentner C; Mundhenk J
    J Endourol; 2019 Feb; 33(2):100-106. PubMed ID: 30526029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project.
    Scheltema MJ; Tay KJ; Postema AW; de Bruin DM; Feller J; Futterer JJ; George AK; Gupta RT; Kahmann F; Kastner C; Laguna MP; Natarajan S; Rais-Bahrami S; Rastinehad AR; de Reijke TM; Salomon G; Stone N; van Velthoven R; Villani R; Villers A; Walz J; Polascik TJ; de la Rosette JJMCH
    World J Urol; 2017 May; 35(5):695-701. PubMed ID: 27637908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.
    von Hardenberg J; Cash H; Koch D; Borkowetz A; Bruendl J; Leyh-Bannurah SR; Kuru TH; Kowalewski KF; Schindele D; Mala KS; Westhoff N; Blana A; Schostak M;
    World J Urol; 2021 Oct; 39(10):3747-3754. PubMed ID: 33881557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.